Karyopharm Therapeutics Inc. Common Stock (KPTI)
Stock · NASDAQ · Health Care
$0.3861as of 10/16/2026
Price chart
Active signals
KPTI Signal Track Record
How signals performed across all stocks →What KPTI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -3.3% | 47% | September 11, 2026 |
| Bollinger Band Breakdown | 22 | +1.2% | 59% | September 29, 2026 |
| Bollinger Band Breakout | 19 | -10.7% | 26% | June 26, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -3.2% | 33% | April 6, 2026 |
| Any 20-session window (baseline) | -5.2% | 38% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 228
- Website
- karyopharm.com/
Fundamentals
- 1-day range
- $0.33$0.4
- Market cap
- $44.19M
- P/E (trailing)
- —
- P/E (forward)
- -0.14
- EPS (trailing)
- $-12.84
- Dividend yield
- —
- Beta
- 1.12
- Avg. volume
- 1.79M
How Karyopharm Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 13, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Karyopharm Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- KPTIKaryopharm Therapeutics Inc. Common Stock$0.39▲ 11.11%Market cap $44.19MP/E —$0.31$10.99
- EDSAEdesa Biotech Inc. Common Shares$2.57▼ 3.75%Market cap $44.90MP/E —$0.72$20.32
- CNTXContext Therapeutics Inc. Common Stock$0.244▲ 1.24%Market cap $46.31MP/E —$0.2501$3.62
- FLNAFilana Therapeutics Inc. Common Stock$0.7▼ 7.89%Market cap $46.33MP/E —$0.6701$2.27
- PDSBPDS Biotechnology Corporation Common Stock$1.13▼ 13.08%Market cap $41.78MP/E —$0.1952$1.79
- MREOMereo BioPharma Group plc American Depositary Shares$0.303▼ 1.94%Market cap $47.46MP/E —$0.2$2.37
- HYPDHyperion DeFi Inc. Common Stock$2.84▼ 9.84%Market cap $40.47MP/E 7.24$2.34$9.13
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics Inc. Common Stock | $44.19M | — | $0.39 | ▲ 11.11% | $0.31$10.99 |
| EDSA Edesa Biotech Inc. Common Shares | $44.90M | — | $2.57 | ▼ 3.75% | $0.72$20.32 |
| CNTX Context Therapeutics Inc. Common Stock | $46.31M | — | $0.244 | ▲ 1.24% | $0.2501$3.62 |
| FLNA Filana Therapeutics Inc. Common Stock | $46.33M | — | $0.7 | ▼ 7.89% | $0.6701$2.27 |
| PDSB PDS Biotechnology Corporation Common Stock | $41.78M | — | $1.13 | ▼ 13.08% | $0.1952$1.79 |
| MREO Mereo BioPharma Group plc American Depositary Shares | $47.46M | — | $0.303 | ▼ 1.94% | $0.2$2.37 |
| HYPD Hyperion DeFi Inc. Common Stock | $40.47M | 7.24 | $2.84 | ▼ 9.84% | $2.34$9.13 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Karyopharm Therapeutics Extends Forbearance Period To October 15benzinga · 10/14/2026
- Let's have a look at the top gainers and losers in the middle of the day of today's session.ChartMill · 9/11/2026
- Traders are paying attention to the gapping stocks in Friday's session.ChartMill · 9/11/2026
- Which stocks are moving before the opening bell on Friday?ChartMill · 9/11/2026
- Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra useYahoo · 9/11/2026
Insider Activity
Insider Actions →- Abate Kristin · September 1, 2026 · Sale19 @ $2.02
- Poulton Stuart · July 28, 2026 · Sale189 @ $7.1
- Su Zhen · May 21, 2026 · Grant15.5K
- Oliger Christy J. · May 21, 2026 · Grant15.5K
- Chen Schor · May 21, 2026 · Grant15.5K
- Greene Barry E · May 21, 2026 · Grant15.5K
- Deepika Pakianathan · May 21, 2026 · Grant15.5K
- Garen G. Bohlin · May 21, 2026 · Grant15.5K
- Poulton Stuart · May 14, 2026 · Sale403 @ $9.5
- Rangwala Reshma · May 14, 2026 · Sale408 @ $9.5
- Cheng Sohanya Roshan · May 14, 2026 · Sale324 @ $9.5
- Abate Kristin · May 14, 2026 · Sale53 @ $9.5
- Paulson Richard A. · May 14, 2026 · Sale2.2K @ $9.5
- Mano Michael · May 14, 2026 · Sale266 @ $9.5
- Mano Michael · May 13, 2026 · Grant700
Institutional Ownership
March 31, 2026
- Total shares held
- 25.15M
- Total value held
- $129.49M
- Institutional holders
- 80
- Unknown2.57M
- Unknown1.95M
- Unknown1.92M
- Unknown1.81M
- Unknown1.54M
- Unknown1.32M
- Unknown1.18M
- Unknown947.6K
- Unknown897.7K
- Unknown750.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Karyopharm Reports Inducement Grant Under Nasdaq Rule
Karyopharm Therapeutics disclosed an inducement grant made under Nasdaq Listing Rule 5635(c)(4). This type of disclosure is typically required when a company offers equity compensation to a new employee or consultant to induce them to join the firm. The announcement is a standard corporate compliance update rather than a change in business operations or financial results.
Karyopharm Reports Inducement Grant Under Nasdaq Rule. Karyopharm Therapeutics disclosed an inducement grant made under Nasdaq Listing Rule 5635(c)(4). This type of disclosure is typically required when a company offers equity compensation to a new employee or consultant to induce them to join the firm. The announcement is a standard corporate compliance update rather than a change in business operations or financial results.